Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ADMA Biologics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

29 Oct 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ADMA Biologics Inc (ADMA-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

01 Nov 2016 Thomson Reuters Stock Report 12 $25.00

ValuEngine Rating and Forecast Report for ADMA

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

30 Oct 2016 ValuEngine, Inc. 11 $25.00

ADMA BIOLOGICS INC (ADMA=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

29 Oct 2016 Pechala's Reports 2 $25.00

Wright Investors Service Comprehensive Report for Adma Biologics Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

24 Sep 2016 Wright Reports 64 $75.00

Laidlaw: ADMA: 2Q16: Discussions and potential resolutions for issues related to CRL with third parties and the FDA are underway

ADMA recently reported 2Q16 results with a net loss of ($6.0MM) and net loss/share of ($0.50). ADMA ended 2Q16 with cash of ~...

15 Aug 2016 Laidlaw & Company 8 $25.00

Laidlaw: ADMA: RI-002 as an intravenous immune globulin (IVIG) For PIDD BLA received CRL

Last Friday after market close, ADMA reported that it has received a complete response letter (CRL) for its BLA of RI-002 as ...

01 Aug 2016 Laidlaw & Company 9 $25.00

Laidlaw: ADMA: RI-002 in RSV prevention of PIDD PDUFA dates potentially to come in days

ADMA filed a BLA for RI-002 as an IVIG in patients suffering from primary immune deficiency disease (PIDD) in late July 2015....

27 Jul 2016 Laidlaw & Company 9 $25.00

Laidlaw: ADMA: 1Q16: With cash shortfall concerns behind It, likely RI-002 in RSV prevention of PIDD approval is fast approaching

ADMA recently reported 1Q16 results with a net loss of ($4.6MM) vs. Laidlaw ($4.8MM) and the Street ($4.0MM) estimates. Net l...

16 May 2016 Laidlaw & Company 8 $25.00

Thomson Reuters Stock Report - ADMA Biologics Inc (ADMA-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 May 2016 Thomson Reuters Stock Report 12 $25.00